Mar 17, 2020
Orexo Presents Sales Potential of the Pharmaceutical Pipeline and Digital Therapies During the Capital Markets Day
Mar 12, 2020
Invitation to Attend Orexo's Capital Markets Day via Teleconference
Mar 06, 2020
Orexo Submits Application for vorvida® to the FDA to Enable Commercialization in the US
Feb 17, 2020
Orexo AB (publ.) has Resolved to Carry out Repurchases of own Shares
Jan 30, 2020
Q4 Incl. Full Year Report 2019
Jan 29, 2020
Promising Results From Human PK Study Assessing Novel Ketorolac Formulations for Treatment of Pain
Dec 03, 2019
Save the Date: Orexo to Host Capital Markets Day focusing on Digital Health, on March 17, 2020
Dec 02, 2019
Orexo Appoints Dennis Urbaniak as Executive Vice President Digital Health
Nov 27, 2019
Orexo Acquires Exclusive US Rights to Commercialize Vorvida®, a Digital Therapy for Alcohol Use Disorder with Scientifically Proven Efficacy
Nov 08, 2019
Orexo to Present at Jefferies 2019 Healthcare Conference
Oct 24, 2019
Orexo Interim Report Q3 2019
Jul 11, 2019
Orexo Interim Report Q2 2019
Jul 10, 2019
Orexo Signs License and Supply Agreement With Mundipharma for Zubsolv® in Australia and New Zealand
Jul 09, 2019
Orexo Prepays Part of the Corporate Bond Loan
Jun 28, 2019
Number of Shares and Votes in Orexo
Jun 12, 2019
Issue and Repurchase of Class C Shares
May 31, 2019
Number of Shares and Votes in Orexo
May 17, 2019
Orexo's Closest Upcoming Presentations at Conferences
May 02, 2019
Orexo: Interim Report Q1 2019
Apr 26, 2019
Issues of Shares Following the Vesting of 2016/2019 Incentive Plan